A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Expert perspectives on a recent clinical trial readout indirectly comparing acalabrutinib and zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
EP. 1: Relapsed/Refractory CLL: Overview of the Treatment Landscape
A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
EP. 2: Clinical Trials With BTK Inhibitors in Relapsed/Refractory CLL
Focused discussion on key clinical trial data behind currently available BTK inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia.
EP. 3: Indirect Comparison of Acalabrutinib Versus Zanubrutinib in RR CLL: Efficacy Analysis
Alan Skarbnik, MD, and Ryan Jacobs, MD, review efficacy data from the indirect comparison study of acalabrutinib versus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia.
EP. 4: Indirect Comparison of Acalabrutinib Versus Zanubrutinib in RR CLL: Safety Analysis
Key safety data from the indirect comparison study of acalabrutinib versus zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
EP. 5: Relapsed/Refractory CLL: Key Takeaways and Ongoing Challenges
Closing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.
